GlassScriptPhysician profile
Stephanie Baker
NPI 1013903467
$1,713.20
in general payments reported to CMS, 2019-2025
15 companies · $319 in 2025
The $319 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $72.60 · 2021: $96.27 · 2022: $270 · 2023: $415 · 2024: $431 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $390.63 | 2019-2025 | |
| Seqirus USA INC | $283.48 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $272.98 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $198.75 | 2019-2025 | |
| Kaleo, INC. | $159.31 | 2020-2024 | Auvi-Q |
| Cranial Technologies, INC | $127.85 | 2019-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $71.10 | 2024 | |
| Noven Therapeutics, LLC | $42.30 | 2024 | Xelstrym |
| Alexion Pharmaceuticals, INC. | $30.92 | 2024 | Strensiq |
| Alk-Abello, INC | $26.38 | 2025 | Neffy |
| Acadia Pharmaceuticals INC | $25.59 | 2023 | Daybue |
| Neuronetics, INC. | $22.47 | 2025 | Neurostar Tms Therapy System |
| Tris Pharma INC | $21.28 | 2022 | |
| Sobi, INC | $20.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.